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Abstract
Context
Gastroenteritis remains a leading cause of childhood morbidity.
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Objective
Because prior reviews have focused on isolated symptoms and studies conducted in developing countries, this study focused on interventions commonly considered for use in developed countries. Intervention specific, patient-centered outcomes were selected.

Data Sources
MEDLINE, EMBASE, the Cochrane Database of Systematic Reviews, trial registries, grey
literature, and scientific meetings.

Study Selection
Randomized controlled trials, conducted in developed countries, of children aged <18
years, with gastroenteritis, performed in emergency department or outpatient settings which
evaluated oral rehydration therapy (ORT), antiemetics, probiotics or intravenous fluid
administration rate.
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Data Extraction
The study was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions and the PRISMA guidelines. Data were independently extracted by
multiple investigators. Analyses employed random effects models.

Results
31 trials (4,444 patients) were included. ORT: Compared with intravenous rehydration, hospitalization (RR 0.80, 95%CI 0.24, 2.71) and emergency department return visits (RR 0.86,
95%CI 0.39, 1.89) were similar. Antiemetics: Fewer children administered an antiemetic required intravenous rehydration (RR 0.40, 95%CI 0.26, 0.60) While the data could not be
meta-analyzed, three studies reported that ondansetron administration does increase the
frequency of diarrhea. Probiotics: No studies reported on the primary outcome, three studies evaluated hospitalization within 7 days (RR 0.87, 95%CI 0.25, 2.98). Rehydration: No
difference in length of stay was identified for rapid vs. standard intravenous or nasogastric
rehydration. A single study found that 5% dextrose in normal saline reduced hospitalizations
compared with normal saline alone (RR 0.70, 95% CI 0.53, 0.92).

Conclusions
There is a paucity of patient-centered outcome evidence to support many interventions.
Since ORT is a low-cost, non-invasive intervention, it should continue to be used. Routine
probiotic use cannot be endorsed at this time in outpatient children with gastroenteritis.
Despite some evidence that ondansetron administration increases diarrhea frequency,
emergency department use leads to reductions in intravenous rehydration and hospitalization. No benefits were associated with ondansetron use following emergency department
discharge.

Introduction
Gastroenteritis results in nearly 2 million pediatric emergency department (ED) visits in the
United States annually.[1] Although rotavirus vaccination has altered the epidemiology of
acute gastroenteritis (AGE),[2] emerging pathogens such as norovirus[3] continue to result in
symptoms prompting medical evaluation.[4]
While systematic reviews (SR) have evaluated treatment options,[5–11] they are often inconclusive or discordant. Recent guidelines published by European Society for Pediatric
Gastroenterology, Hepatology and Nutrition (EPGHAN) and the European Society of Pediatric Infectious Diseases (ESPID)[12] and those issued by the National Institute for Health and
Clinical Excellence (NICE)[13] are vague regarding their recommendation regarding the use of
antiemetics, a therapy endorsed by other position papers and meta-analyses.[10,11,14] The
aforementioned guidelines also have differing recommendations regarding probiotics
(Table 1).[15] The most recent guidelines endorsed by the American Academy of Pediatrics
were published over a decade ago.[16]
Participant eligibility criteria in 'gastroenteritis' studies can vary significantly between studies. Since the diagnosis is made on clinical grounds, the precision is debatable. Most clinical trials employ clearly defined clinical features to determine eligibility. As these studies reflect
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Table 1. Summary of differing recommendations of prominent gastroenteritis guidelines.
Antiemetics

Probiotics

Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio
A, Shamir R, Szajewska H European society for
pediatric gastroenterology, hepatology, and
nutrition/european society for pediatric infectious
diseases evidence-based guidelines for the
management of acute gastroenteritis in children
in europe: update 2014. J Pediatr Gastroenterol
Nutr 2014, 59:132–152.

Ondansetron, at the dosages used in the
available studies and administered orally or
intravenously, may be effective in young children
with vomiting related to AGE. Before a ﬁnal
recommendation is made, a clearance on
safety in children is, however, needed (II, B)
(strong recommendation, low-quality evidence).

Administration of effective probiotic strains
reduce the duration of hospital stay and may
be considered in children admitted with AGE
(II, B) (strong recommendation, low quality
evidence). Active treatment with probiotics, in
adjunct to ORS, is effective in reducing the
duration and intensity of symptoms of
gastroenteritis. Selected probiotics can be used
in children with AGE (I, A) (strong
recommendation, moderate-quality evidence).
New evidence has conﬁrmed that probiotics are
effective in reducing the duration of symptoms in
children with AGE (I, A) (strong recommendation,
moderate-quality evidence). The use of the
following probiotics should be considered in
the management of children with AGE as an
adjunct to rehydration therapy: L rhamnosus GG
and S boulardii (I, A) (strong recommendation,
low-quality evidence).

National Collaborating Centre for Women's and
Children's Health Diarrhoea and vomiting caused
by gastroenteritis: diagnosis, assessment and
management in children younger than 5 years.
Commissioned by the National Institute for
Health and Clinical Excellence; Available at:
http://www.nice.org.uk/guidance/cg84/resources/
cg84-diarrhoea-and-vomiting-in-children-under-5full-guideline2. Accessed October 15, 2014.

The guideline development group (GDG)
considered that evidence from randomised
controlled trials indicated that oral ondansetron
could increase the success rate with oral
rehydration therapy. The GDG was concerned
that ondansetron might have adverse effects
such as worsening diarrhoea. There was no
evidence to support other agents, including
metoclopramide and dexamethasone. The GDG
concluded that administration of anti-emetics
could not currently be recommended.

There was evidence from a high-quality
systematic review suggesting that probiotic
treatment had a beneﬁcial effect–shortening the
duration of diarrhoea and reducing the stool
frequency. However, the available studies varied
in quality, in the speciﬁc probiotics studied, in the
treatment regimens used and in the outcomes
examined. Therefore, despite some evidence of
possible clinical beneﬁt, the GDG did not
consider it appropriate to recommend the use
of a probiotic at this time.

Cheng A, Canadian Paediatric Society—Acute
Care Committee Emergency department use of
oral ondansetron for acute gastroenteritis-related
vomtiing in infants and children. Paediatr Child
Health 2011, 16:177–179.

Oral ondansetron therapy, as a single dose,
should be considered for infants and children
six months to 12 years of age who present to
the ED with vomiting related to suspected acute
gastroenteritis, and who have mild to moderate
dehydration or who have failed oral rehydration
therapy.

Not applicable.

Piescik-Lech M, Shamir R, Guarino A,
Szajewska H Review article: the management of
acute gastroenteritis in children. Aliment
Pharmacol Ther 2013, 37:289–303.

New evidence indicates that ondansetron, at the
dosages used in the studies and administered
orally or intravenously, may be considered for
use in young children with vomiting related to
AGE. However, before a ﬁnal recommendation is
made, a clearance on safety in children is
needed.

New evidence has conﬁrmed that the
probiotics currently supported by ESPGHAN/
ESPID–Lactobacillus GG and S. boulardii–are
effective in reducing the duration of
diarrhoea. Current evidence clearly indicates
that these are not the only effective probiotic
microorganisms; however, these are the most
studied. Probiotic effects are strain-speciﬁc, so
the efﬁcacy and safety of each should be
established.

King CK, Glass R, Bresee JS, Duggan C
Managing acute gastroenteritis among children:
oral rehydration, maintenance, and nutritional
therapy. MMWR Recomm Rep 2003, 52:1–16.

No clear recommendation in report.

Ondansetron, a serotonin antagonist, either by
the oral or IV route, can be effective in
decreasing vomiting and limiting hospital
admission. However, reliance on pharmacologic
agents shifts the therapeutic focus away from
appropriate ﬂuid, electrolyte, and nutritional
therapy, can result in adverse events, and can
add unnecessarily to the economic cost of
illness. Because acute diarrhea is a common
illness, cost-effective analyses should be
undertaken before routine pharmacologic
therapy is recommended.

doi:10.1371/journal.pone.0128754.t001
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pragmatic considerations and employ randomization, they retain internal validity. However,
without careful consideration, their grouping together in SR and meta-analyses can be problematic. Consequently, significant variation has been documented in the management of AGE
in developed countries at institutional,[17] national,[18] and international levels.[19]. This is
in part explained by heterogeneity–population, setting, etiologic agents, and nutritional status.
Studies from low and middle income countries include more severe cases, organisms rarely
seen in developed nations, and malnourished children.[20,21] Outcome selection is increasingly a concern with most SRs focusing on diarrhea duration–a single symptom which in addition
to being heterogeneous itself, also overlooks other key symptoms (e.g. vomiting). An analysis
of 138 pediatric AGE randomized clinical trials (RCT) identified 64 unique definitions of diarrhea, and 69 of “resolution.”[22]
Driven by recent evidence and uncertainties in practice, the efficacy of oral rehydration
therapy (ORT), antiemetics, probiotics and intravenous rehydration in developed countries
was evaluated.

Methods
A protocol (S1 File) was established a priori and followed standard SR procedures.[23] The
planned approach involved initially conducting a comprehensive search to identify all relevant
SRs performed to date to ensure that previously identified relevant studies were included in the
review. This was followed by a thorough search for additional studies. Lastly, the evidence focusing on studies of outpatient children in developed countries was re-examined.

Information Sources and Searches
A medical librarian (A.M.) developed the search strategy in collaboration with the research
team to identify previous SRs of: (1) ORT; (2) antiemetics; (3) probiotics; and (4) intravenous
fluid therapy (IVT). The following sources were searched: (a) MEDLINE (2000 to April 2012),
EMBASE (2000 to April 2012), and the Cochrane Database of Systematic Reviews (2005 to
April 2012) via the OvidSP platform; (b) appropriate journals and major, relevant scientific
meetings; (c) reference lists of relevant reviews; and (d) primary authors were contacted. The
search was not restricted by language or publication status. All studies contained in previous
relevant SRs were screened for inclusion. This approach is an economically efficient method of
identifying all prior relevant studies dating back to the origins of the search engines.
The librarian then searched the literature to identify trials published since the dates included in the earliest SR identified. The search included electronic databases (i.e. MEDLINE,
EMBASE, Cochrane Central Register of Controlled Trials; S2 File) and the grey literature. The
latter search included clinical trials registries (clinicaltrials.gov, the World Health Organization
trials registry, and the Current Controlled Trials registry) and conference proceedings (Society
for Pediatric Research, American Academy of Pediatrics, Canadian Pediatric Society, International Conference on Emergency Medicine; 2010–2012). Reference lists were screened and experts contacted. No language restrictions were employed. The search was re-run in September
2014 to identify any recently published studies.

Inclusion Criteria
Search results were screened independently by two reviewers to identify potentially relevant citations. The full text of potentially relevant citations was assessed for inclusion by two independent reviewers using predefined criteria. Disagreements were resolved by consensus. Eligible
RCTs involved children <18 years of age with AGE and evaluated: (1) any ORT regimen vs. intravenous or nasogastric rehydration; (2) any antiemetic medication vs. placebo or alternative;
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(3) any probiotic agent vs. placebo or alternative; and (4) different rates and compositions of
intravenous fluid rehydration protocols. Studies were included if the condition evaluated was
consistent with AGE and the location was an ED or similar outpatient setting in a developed
nation as defined by the United Nations (i.e. Australia, Canada, European countries, Japan,
New Zealand, and the United States).[24]

Outcomes
The interventions and outcome measures were identified by clinician authors (SF, KB, EF, SG)
and knowledge users (DJ, FB, BH, MJ, TK) a priori based on clinical relevance incorporating
recommendations to employ outcomes of interest to parents, clinicians, and health systems
(Table 2).[25]

Data Extraction
As is commonly performed, one reviewer extracted data using a structured form with verification performed by a second reviewer.[26–29] Items extracted were: study characteristics, participants, interventions and comparisons, outcomes, funding source, and results. Data were
entered into Microsoft Excel (Microsoft, Redmond, WA). Disagreements were resolved by consensus, or by a third reviewer.

Risk of Bias Assessment
The Cochrane Risk of Bias (RoB) tool[23] was applied, independently by two reviewers to assess internal validity (S1 Table). Discrepancies were resolved by consensus or by involving a
third reviewer.
Table 2. Interventions and their specific outcomes evaluated.
Primary Outcome

Secondary Outcomes
Oral Rehydration Therapy

Hospitalization

Length of Stay
Return Visits
Adverse Effects
Antiemetic Agents

Administration of Intravenous Rehydration

Hospitalization
Length of Stay
Return Visits
Adverse Effects
Probiotic Agents

Any Subsequent Healthcare Visit (7 days)

Administration of Intravenous Rehydration
Hospitalization
Adverse Effects

Intravenous Fluid Therapy
Length of Stay

Hospitalization
Return Visits
Dysnatremia*

*The term dysnatremia refers to the presence of a serum sodium value outside of the age accepted range
of normal values.
doi:10.1371/journal.pone.0128754.t002
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Grading the Body of Evidence
The quality of evidence was assessed using methods developed by the GRADE Working
Group.[30] For each comparison and outcome, the following were assessed: risk of bias, consistency, directness, and precision. Overall quality was graded as high, moderate, low, or very low
by two reviewers with discrepancies resolved through discussion.

Statistical Analysis
Evidence tables to describe the studies were developed. A quantitative analysis synthesized numerically the effectiveness of each intervention and investigated heterogeneity. Data was reported for continuous outcomes as mean differences which were combined, where appropriate,
using a weighted mean difference and inverse-variance methods.[31] Data for dichotomous
outcomes are reported employing risk ratios (RR) or risk differences. The latter was employed
when there were zero events in one of the treatment arms of an individual study which contributed data to the meta-analysis (e.g. adverse events). Results are reported with 95% confidence
intervals. The primary analysis was based on a random effects model due to anticipated clinical
variability between studies.[32] Sensitivity analyses were conducted using a fixed effects model
and no differences were identified in the results. Heterogeneity was quantified using the Isquared statistic.[33,34] When heterogeneity was substantial (I2 75%), pooling of studies was
not performed. Due to insufficient numbers pre-planned sensitivity analyses based on risk of
bias, intention-to-treat analysis, and funding source could not be conducted. Testing for publication bias was not performed due to insufficient numbers. Analyses were conducted using Review Manager 5.0 (The Cochrane Collaboration, Copenhagen, Denmark).

Results
Sixty-six RCTS were relevant; 35 did not report any of the a priori identified outcomes of interest, therefore, 31 RCTs involving 4,444 patients were included (Fig 1; Table 3). Four antiemetic
agents were studied along with 11 different probiotic strains. Overall risk of bias was low for
23% of trials (7/31), unclear for 74% (23/31), and high for 3% (1/31); S1 Table. Industry funding was identified in the following studies: ORT – 5 (50%); antiemetics – 3 (38%); probiotics – 2
(33%); IVT – 2 (33%).

Oral Rehydration Therapy (ORT)
Ten studies involving 599 patients compared ORT with IVT (S2 Table). Sample sizes ranged
from 24 to 111 (median 47, inter-quartile range 35 to 91). Five studies did not report dehydration severity; the remainder, with one exception,[35] included primarily children with mild
dehydration.
Three studies provided data on the effect for the primary outcome of hospitalization, which
in meta-analysis, showed no significant difference between groups (RR 0.80, 95% CI 0.24, 2.71,
I2 = 51%; Table 4; Fig 2). The quality of evidence was low owing to inconsistencies in effect estimates across studies and imprecision in the pooled result. No difference was observed in the
secondary outcome of return to the ED. Six studies provided data on ED length of stay. However, there was substantial heterogeneity across studies and results could not be pooled (I2 =
91%). Quality of the evidence was very low. The mean difference in length of stay reported by
individual studies, including time spent in hospital, ranged from 1.20 days less for ORT (95%
CI -2.16, -0.24) to 0.92 days longer (95% CI 0.31, 1.53). Five studies reported on adverse effects
(Table 5); no significant differences were identified.
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Fig 1. Flow diagram of study selection. SR, systematic review; PICO, Population, Intervention, Comparison, Outcome; RCT, randomized controlled trial.
doi:10.1371/journal.pone.0128754.g001

Antiemetics
Nine studies involving 1,691 patients evaluated three antiemetic agents: ondansetron (N = 6),
dimenhydrinate (N = 2), and granisetron (N = 1). Eight RCTs compared the antiemetic agent
with placebo; one RCT compared ondansetron with dexamethasone (Table 3; Fig 3; S3 Table).
Table 3. Overview of studies included in systematic review.
Comparison

Number of
studies
(Number of
patients)

Number of studies
providing data for
primary outcome
(Number of patients)

Number of studies
providing data for
secondary outcomes
(Number of patients)

Years of
publication,
median (range)

Countries of study
(Numer of studies)

Risk of
bias

Intravenous Therapy
vs. Oral Rehydration
Therapy

10 (599)

3 (136)

10 (599)

1992 (1985–
2005)

Australia (1), Canada
(1), Finland (1), USA
(7)

9 unclear,
1 low

Any Antiemetic vs.
Placebo

9 (1691)

7 (1043)

9 (1691)

2008 (2002–
2014)

Australia (1), Canada
(1), Germany (1),
Saudi Arabia (1),
USA (5)

7 unclear,
2 low

Any Probiotic vs.
Placebo

6 (1170)

1 (155)

6 (1170)

2009 (2007–
2012)

Australia (1), Italy (2),
Ukraine (2), USA (1)

4 unclear,
2 low

Intravenous Fluid
Rates &
Compositions

6 (984)

2 (305)

4(644)

2011 (2006–
2014)

Australia (2), Canada
(1), USA (1)

3 unclear,
2 low, 1
high

doi:10.1371/journal.pone.0128754.t003
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Table 4. Results for Primary and Secondary Outcomes.
Comparison

Outcome

Number of studies (Number of
patients)

Risk Ratio (95% CI)

I2
(%)

Quality of evidence based on
GRADE

Oral Rehydration Therapy
IVT vs. ORT
Primary

Hospitalization

3 (136)

0.80 (0.24, 2.71)

51

Low

Secondary

Length of ED Stay

6 (308)

Not pooled due to substantial
heterogeneity

91

very low

Return to ED

3 (193)

0.86 (0.39, 1.89)

0

moderate

High

Antiemetics
Any antiemetic vs. placebo
Primary

IV Fluid Administration

5 (733)

0.40 (0.26, 0.60)†

30

Secondary

Hospitalization

7 (1043)

0.44 (0.23, 0.82)†

27

High

Return to ED

8 (1074)

1.31 (0.73, 2.35)

52

moderate

Length of ED Stay

5 (991)

Not pooled due to substantial
heterogeneity

75

moderate

Primary

IV Fluid Administration

1 (144)

0.74 (0.29, 1.87)

NA

low

Secondary

Hospitalization

2 (368)

0.72 (0.34, 1.53)

0

moderate

Return to ED

2 (343)

0.61 (0.34, 1.12)

0

moderate

Dimenhydrinate vs. placebo

Ondansetron vs. dexamethasone
Primary

Hospitalization

1 (93)

0.29 (0.06, 1.33)

NA

low

Secondary

Return to ED

1 (56)

4.30 (1.00, 18.47)†

NA

low

Primary

IV Fluid Administration

3 (433)

0.38 (0.27, 0.54)†

0

High

Secondary

Hospitalization

5 (613)

0.32 (0.18, 0.57)†

2

moderate

Return to ED

5 (609)

1.57 (0.70, 3.52)

36

Low

Length of ED Stay

4 (826)

Not pooled due to substantial
heterogeneity

NA

moderate

Primary

IV Fluid Administration

1 (156)

0.05 (0.00, 0.78)

NA

Very low

Secondary

Hospitalization

1 (165)

3.04 (0.13, 73.46)

NA

Very low

Return to ED

1 (122)

3.09 (1.19, 8.05)

NA

Very low

Length of ED Stay

1 (165)

-0.65 (-1.29, -0.01)

NA

Very low

Ondansetron vs. placebo

Granisetron vs. placebo

Probiotics
Probiotic (Any) vs. Placebo
Primary

Return to ED

1 (155)

0.78 (0.36, 1.67)

NA

Low

Secondary

Hospitalization

3 (833)

0.53 (0.26, 1.07)

20

Low

IV Fluid Administration

1 (64)

1.13 (0.81, 1.57)

NA

Low

NA

very low

NA

very low

NA

very low

NA

Low

NA

Low

Probiotic (Combo) vs. Placebo
Secondary

Hospitalization

1 (189)

0.47 (0.09, 2.53)
B. clausii vs. Placebo

Secondary

Hospitalization

1 (192)

0.92 (0.24, 3.57)
E. faecium vs. Placebo

Secondary

Hospitalization

1 (183)

Secondary

IV Fluid Administration

1 (64)

1.01 (0.26, 3.92)
L. casei vs. Placebo
1.13 (0.81, 1.57)
L. paracasei vs. Placebo

Secondary

Hospitalization

1 (107)

0.37 (0.18, 0.75)†
L. rhamnosus vs. Placebo

(Continued)
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Table 4. (Continued)
Comparison

Outcome

Number of studies (Number of
patients)

Risk Ratio (95% CI)

I2
(%)

Quality of evidence based on
GRADE

Primary

Return to ED

1 (155)

0.78 (0.36, 1.67)

NA

very low

Secondary

Hospitalization

2 (347)

0.65 (0.08, 5.45)

43

very low

NA

very low

S. boulardii vs. Placebo
Secondary

Hospitalization

1 (183)

1.01 (0.26, 3.92)
IV Fluids
Rapid IV vs. Standard IV

Primary

Length of ED Stay >6
hours

1 (226)

1.06 (0.74, 1.53)

NA

low

Secondary

Hospitalization

2 (318)

1.03 (0.44, 2.39)

23

low

Return to ED

2 (311)

0.88 (0.52, 1.48)

0

low

Rapid NG vs. Standard NG
Primary

Length of ED Stay*

1 (228)

-1.90 (-9.11, 5.31)

NA

very low

Secondary

Hospitalization

1 (228)

0.69 (0.49, 0.97)†

NA

low

NA

very low
Very low

Isotonic IV Fluid vs. Hypotonic IV Fluid
Secondary

Dysnatremia

1 (44)

-0.23 (-0.41, -0.04)†
5% Dextrose in Normal Saline vs. Normal Saline

Primary

Length of ED Stay

1 (188)

0.13 (-0.27, 0.53)

NA

Secondary

Hospitalization

1 (114)

0.70 (0.53, 0.92)

NA

Very low

Return visits

1 (80)

0.64 (0.30, 1.36)

NA

Very low

Hospitalization

1 (54)

NA

Very low

Plasma-Lyte A vs. 0.9% Sodium Chloride
Secondary

1.09 (0.59, 2.03)

IVT, Intravenous Therapy; ORT, Oral Rehydration Therapy; ED, Emergency Department; GRADE, Grading of Recommendations Assessment,
Development and Evaluation; IV, intravenous; NA, Not Applicable; NG, nasogastric; vs, versus.
† Statistically signiﬁcant effect.
*Length of stay, as a continuous variable, is reported as mean difference (95% CI).
doi:10.1371/journal.pone.0128754.t004

All five studies demonstrated a reduction in the primary outcome of intravenous rehydration
usage amongst children administered an antiemetic agent (Fig 3; RR 0.40, 95% CI 0.26, 0.60,
I2 = 30%; N = 733). Quality of evidence for this outcome was high. Pooled results demonstrated
that patients receiving an antiemetic agent were hospitalized less often (RR 0.44, 95% CI 0.23, 0.82,
I2 = 27%; N = 1043). There was substantial heterogeneity for length of stay results across studies
(I2 = 75%); therefore, data were not pooled. Mean length of stay reported in individual studies ranged from 0.23 hours (95% CI -0.49, 0.03) to 1.0 hours (95% CI -1.34, -0.66) less for antiemetics.
There was no difference between groups in the proportions of children experiencing ED revisits.
Findings were similar when only those studies involving ondansetron were analyzed. No
significant differences were identified when studies involving dimenhydrinate were evaluated.
Three studies evaluating dimenhydrinate reported specific adverse events—drowsiness, headache, rash, hyperactivity, gastrointestinal upset, and sedation; no differences were noted compared with placebo (Table 5).
Diarrhea frequency was evaluated in several studies but due to the varying methods of reporting the findings, the results could not be combined. Following a single dose of ondansetron
or placebo, during ED ORT one study (N = 215) reported that ondansetron administration
resulted in a statistically significant increase in diarrhea frequency (1.4 vs. 0.5 stools; group
(P < 0.001).[36] Another study, which similarly evaluated single oral dose ondansetron vs. placebo, collected post-discharge diarrhea frequency information. In their cohort (N = 106), the
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median number of episodes of diarrhea post-discharge was 0 in both groups; 93% of children
administered placebo and 80% of those administered ondansetron had < 3 episodes of diarrhea after discharge and the mean was 1.8 vs. 0.5 episodes of diarrhea respectively (no test of
significance provided).[37] A multi-dose ondansetron vs. placebo study (N = 145) reported no
difference in stool frequency while in the ED (mean 0.70 vs. 0.61 episodes respectively;
P = 0.62); however, following discharge there was a significant increase in stool frequency
amongst those administered ondansetron at both 24 (4.7 vs. 1.4; P = 0.002) and 48-hour (3.0
vs. 1.0; P = 0.02) outcome time points.[38] A study evaluating single dose, intravenous ondansetron (N = 107), reported that compared with placebo, there were no significant differences in
the proportion (41%—ondansetron; 40%—placebo; P = 0.93), frequency (median of 5 in both
groups; P = 0.87) or duration (60 hours in the ondansetron vs. 49 hours in placebo groups;
P = 0.72) of diarrheal episodes following the intervention.[39] Lastly, a multi-dose study of
granisetron (N = 165) reported a similar odds (OR 1.29, 95% CI 0.64, 2.60) and frequency of
diarrhea following medication administration (6.5 ± 6.1 vs. 5.8 ± 7.6; P = 0.51).[40]

Probiotics
Six studies, involving 1170 patients, examined different probiotics (Table 4; S4 Table); five
compared individual probiotic agents with placebo, one compared multiple and combination
products with placebo.

Fig 2. Meta-graph comparing oral rehydration therapy vs. intravenous fluid therapy. Results from meta-analysis of direct comparisons of oral
rehydration therapy vs. intravenous fluid therapy on the outcomes of admission to hospital from the emergency department and revisits to the emergency
departments, displayed employing Forest plots.
doi:10.1371/journal.pone.0128754.g002
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No studies reported findings related to any subsequent healthcare provider visits. One study
reported no difference between groups in terms of return for additional ED care (Fig 4 and
Table 4). Pooled results from 3 studies showed no difference between groups for hospitalization
within 7 days (RR 0.53, 95% CI 0.26, 1.07, I2 = 20%; N = 571). Based on one study, no difference was observed between probiotic and placebo groups in the need to administer intravenous
rehydration within 7 days.
When analyzed by individual probiotic product, most comparisons included a single RCT
and reported no significant differences between groups. The quality of evidence for all comparisons was low or very low. Specific adverse events were reported in only one study; no differences were found between groups (Table 5).

Intravenous Fluid Therapy (IVT)
Six studies involving 984 patients compared different rates or compositions of intravenous fluids (S5 Table). Two studies (N = 318) compared rapid (60 ml/kg and 50 ml/kg over 1 hour) vs
Table 5. Adverse Events.
Risk Difference (95%
CI)

Risk Ratio* (95%
CI)

I2
(%)‡

IVT 6/99 (6); ORT 8/120 (7)

0.03 (-0.07, 0.13)

1.30 (0.29, 5.87)

54
NA

Adverse Event

Total number of
patients

Number of events/total (%)

Periorbital
Edema

219

IVT vs ORT

Hyponatremia

104

IVT 3/52 (6); ORT 4/52 (8)

0.02 (-0.08,0.12)

1.33 (0.31, 5.67)

Seizure

152

IVT 1/67 (1); ORT 1/85 (1)

0.00 (-0.07, 0.08)

0.70 (0.04, 11.94)

31

Phlebitis

52

IVT 0/17 (0); ORT 0/35 (0)

0.00 (-0.08, 0.08)

-

NA

Headache

137

Dimenhydrinate 3/69 (4); Placebo 1/68 (2)

0.03 (-0.03, 0.08)

2.96 (0.32, 27.72)

NA

Rash

137

Dimenhydrinate 4/69 (6); Placebo 0/68 (0)

0.06 (0.00, 0.12)

-

NA

Antiemetics

Hyperactivity

137

Dimenhydrinate 4/69 (6); Placebo 0/68 (0)

0.06 (0.00, 0.12)

-

NA

GI Upset

137

Dimenhydrinate 3/69 (4); Placebo 3/68 (3)

0.00 (-0.07, 0.07)

0.99 (0.21, 4.71)

NA

Sedation

208

Dimenhydrinate 22/106 (22); Placebo 18/102
(19)

0.03 (-0.08, 0.14)

1.18 (0.67, 2.06)

NA

Exanthem

208

Dimenhydrinate 1/106 (1); Placebo 1/102 (1)

0.00 (-0.03, 0.03)

0.96 (0.06, 15.18)

NA

Drowsiness

137

Dimenhydrinate 29/69 (46); Placebo 25/68 (37)

0.01 (-0.02, 0.22)

1.14 (0.75, 1.73)

0

Urticaria

214

Ondansetron 0/107 (0); Placebo 1/107 (1)

-0.01 (-0.03, 0.02)

-

NA
NA

Probiotics
Rhinitis

113

Escherichia coli Nissle 1/55 (2); Placebo 0/58 (0)

0.02 (-0.03, 0.07)

-

Otitis Media

113

Escherichia coli Nissle 1/55 (2); Placebo 0/58 (0)

0.02 (-0.03, 0.07)

-

NA

Abdominal Pain

261

Escherichia coli Nissle 2/130 (1); Placebo 4/131
(3)

0.01 (-0.07, 0.05)

0.67 (0.06, 7.97)

60

Hypersensitivity

151

Escherichia coli Nissle 1/75 (1); Placebo 0/76 (0)

0.01 (-0.02, 0.05)

-

NA

-

NA

0.97 (0.06, 15.00)

NA

Isotonic IV Fluids vs Hypotonic IV Fluids
Dysnatremia

44

Isotonic solution 0/20 (0); Hypotonic solution 5/
22 (23)

Dysnatremia

75

Plasma-Lyte A 1/38 (3)0.9% Sodium Chloride 1/
37 (3)

-0.23 (-0.41, -0.04)†

Plasma-Lyte A vs. 0.9% Sodium Chloride
0.00 (-0.07, 0.07)

IVT, Intravenous Therapy; ORT, Oral Rehydration Therapy; GI, Gastrointestinal; IV, Intravenous; NA, Not Applicable.
* Risk ratio calculated where there was at least one incidence in each group
† Statistically signiﬁcant difference between groups
‡ Based on risk difference
doi:10.1371/journal.pone.0128754.t005

PLOS ONE | DOI:10.1371/journal.pone.0128754 June 15, 2015

11 / 21

Gastroenteritis Management in Developed Countries

Fig 3. Meta-graph comparing any antiemetic therapy vs. placebo. Results from meta-analysis of direct comparisons of therapy with any antiemetic agent
vs. placebo on the outcomes of administration of intravenous hydration, admission to hospital from the emergency department and revisits to the emergency
departments, displayed employing Forest plots.
doi:10.1371/journal.pone.0128754.g003
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Fig 4. Meta-graph comparing any probiotic therapy vs. placebo. Results from meta-analysis of direct comparisons of therapy with any probiotic agent vs.
placebo on the outcomes of administration of revisits to the emergency department, admission to hospital from the emergency department, and intravenous
hydration, displayed employing Forest plots.
doi:10.1371/journal.pone.0128754.g004

standard rehydration rates (20 ml/kg over 1 hour and 50 ml/kg over 3 hours, respectively); one
study compared rapid polyelectrolyte with rapid nasogastric (NG) rehydration (N = 254); one
study compared isotonic with hypotonic intravenous solutions (N = 124); one study compared
5% dextrose in normal saline solution with normal saline solution alone (N = 188); and, one
study compared Plasma-Lyte A with 0.9% sodium chloride (N = 100).
No difference in length of stay was identified for rapid vs. standard IVT or rapid vs. standard NG rehydration (Table 4). Two studies comparing rapid vs. standard IVT also identified
no difference between groups in admissions or ED revisits. Significantly fewer admissions occurred with rapid compared with standard NG rehydration. The study comparing isotonic vs.
hypotonic IVT did not report on any of the outcomes of interest except for dysnatremia; significantly fewer cases occurred with isotonic intravenous hydration. A reduction in hospitalizations (RR 0.70, 95% CI 0.53, 0.92) was identified when 5% dextrose in normal saline was
compared with normal saline; however, no differences were found for length of ED stay or
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return visits. Similarly, no differences were found for time to rehydration, hospitalization, or
incidence of dysnatremia in the study comparing Plasma-Lyte A with 0.9% sodium chloride.
Quality of evidence for all outcomes and comparisons was low or very low.

Discussion
Key treatment decisions were examined—route of rehydration, use of antiemetics and probiotics, and methods of intravenous and nasogastric rehydration—in a single SR, with a unique
focus on children in developed countries in order to provide information needed by clinician
and knowledge users. Although, the use of antiemetics confers short term benefits in outpatients by reducing intravenous rehydration administration and hospitalization, no difference
was identified in terms of ED revisits. Aside from individual studies which documented positive results, no other interventions evaluated were found to result in improved outcomes. This
must be interpreted with caution because most often there were insufficient numbers of eligible
studies evaluating the outcomes of interest.
The treatment of AGE was approached from a perspective which yielded a paucity of studies
from developed countries that reported on the a priori identified outcome measures. Consequently the findings contradict those of prior reviews which endorse the use of probiotics
based on their ability to reduce the mean duration of diarrhea (by 25 hours), the likelihood of
diarrhea lasting 4 days (risk ratio 0.41; 0.32 to 0.53), and stool frequency on day #2 (mean difference 0.80 stools).[8] However, prior reviews included heterogeneous groups of children and
the importance of the outcomes evaluated has been questioned.[22] Because of the methodological limitations of many of the trials included in prior reviews of probiotics, it is suggested
that the evidence be viewed with caution.[41]
To minimize heterogeneity and maximize relevance the study focused on a well-defined
population, key interventions, and clinically important outcomes. This differs from other reviews that “summarise the more recent data” and search only MEDLINE and The Cochrane
Database of Systematic Reviews.[15] Although a recent overview of reviews reported similar
findings, the methodologies, which differed significantly, resulted in the inclusion of different
studies.[42] Other prior meta-analyses have not restricted their populations to developed regions and have struggled with the inclusion of studies with varying outcome measure definitions (e.g. duration of diarrhea).[22] These two characteristics differentiate this review and
underlie the differences in the studies included compared with others.

Oral Rehydration Therapy
Although ORT is the most fundamental and accepted treatment,[16] studies comparing ORT
to IVT generally provided inadequate descriptions of the severity of dehydration, which drives
treatment decisions.[16] The trials identified were small, often single-centre, and rarely reported sample size calculations.[43] Children with mild dehydration were the typical target
population, reflecting the overuse of IVT in North America.[44] Although no difference in the
primary outcome of hospitalization was identified, in the context of the comparison evaluated
(ORT vs. IVT), this supports the use of ORT.
Although oral rehydration solution (ORS) use per se (i.e. we did not focus on the solution
used) was not evaluated, the conceptual approach of ORT as opposed to IVT was evaluated.
Since ORS remains the cornerstone of AGE management and is considered to be the one of the
top medical discoveries of the 20th century,[45] its effectiveness in children with moderate dehydration was not questioned. Given the paucity of studies identified in this review, to further
reduce IVT use in children with moderate dehydration in developed countries, quality improvement studies documenting the keys to successful knowledge translation in the target
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environments, are needed.[46] Such studies have been called for to enhance the ability to translate research findings into clinical practice to maximize the use of evidence-based therapies.
[47]

Antiemetics
Despite limited endorsement in most practice guidelines,[16] this intervention included the
largest number of children of the interventions included in this study. While the results favoured the use of antiemetics as it relates to short-term outcomes, no difference was identified
in ED revisits. This finding is in keeping with the expectations of single dose use of a medication with relatively short half-life. Although prior reviews have been hesitant to recommend
ondansetron use in light of concerns related to its arrhythmogenic potential,[15] recent evidence has reduced concerns related to single oral dose use in otherwise healthy children.[48]
Although we could not meta-analyze the available data on the impact of antiemetics on diarrhea frequency, the data we report does seem to indicate that ondansetron administration does
increase the frequency of diarrhea. The clinical relevance of this increase (range: 0.1–0.9 stools
while undergoing ORT) in the ED is minimal as reflected by the clinically relevant outcomes of
intravenous rehydration and admission which are both reduced amongst children administered ondansetron relative to placebo. Following discharge, there similarly appears to be an increase in the number of diarrheal episodes and this appears to be most pronounced with multidose therapy. Given the lack of benefit seen with multi-dose therapy and the increased risk of
diarrhea, such regimens are not recommended,[49]

Probiotics
European guidelines state that probiotics “should be considered in the management of children
with AGE as an adjunct to rehydration therapy.”[12] Use in North America remains limited,
and has been reported to be as low as 1% amongst inpatients in large U.S. academic pediatric
centres.[50] Although over 60 studies have been conducted,[8] the current analysis raises concerns as it relates to outcomes evaluated. No studies evaluated the primary outcome identified
as most important by our knowledge users—subsequent healthcare provider visits. This outcome was deemed to reflect a clinically significant benefit to the child and family and extends
beyond simply measuring the absolute number of stools or time to last stool. Furthermore, the
quality of the evidence included was 'very low' or 'low' and a disproportionate number of studies (4 out of 6) emerged from Italy and Ukraine.
This review grouped all probiotic products into a single intervention for analytical purposes.
While not ideal, as not all probiotic preparations are equally effective,[51] it was necessary
given the paucity of studies performed with each individual strain. Additionally, a prebiotic
(nondigestible food that beneficially affects the host by selectively stimulating the growth/activity of colonic bacteria in the colon) plus probiotic (xilooligosaccharides plus arabinogalactan
and Lactobacillus paracasei B21060)[52] study was included in the analyses. Sensitivity analyses, which were conducted when a minimum of two studies employing the same probiotic were
identified, did not produce any changes in the conclusions.
A trend towards reductions in future hospitalizations was detected; although this did not
achieve significance, one could interpret this as evidence of a possible clinical benefit associated
with probiotic use. However, it is challenging to generalize findings from probiotic clinical trials with the most frequently studied strain (Lactobacillus GG) having its benefits confined to
studies conducted outside North America.[41] The only North American outpatient study employing Lactobacillus GG found no difference in the time to normal stool or the number of diarrheal stools.[53]
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Intravenous Fluid Therapy
Few studies evaluating IVT were identified, and limited evidence supporting the use of rapid
rehydration therapy was found. The limited evidence of benefit may relate to the inaccuracy of
dehydration assessment[54] or a delay in the timing between intravascular rehydration and
clinical improvement. As it relates to choice of maintenance IV hydration solution, a single,
low quality study, reported that dysnatremias are more frequent amongst children administered hypotonic fluids.

Overall
Investigators should conduct more sophisticated studies that answer clinically relevant questions employing outcomes of importance to end-users. Pragmatic, comparative effectiveness
trials using factorial or non-inferiority designs and valid outcome measures[55] answering key
questions such as the success of ORT in children with moderate dehydration would significantly enhance the uptake of ORT. Such work is needed to confirm and convince knowledge-users
(if positive) of the utility of interventions such as probiotics. Although multiple meta-analyses
have identified some benefits to be associated with the latter,[8,41] their uptake has been limited. Antiemetics have been investigated employing clinically important outcome measures and
consequently uptake has occurred rapidly.[56] The use of patient-centered outcomes and well
defined patient populations to minimize heterogeneity and maximize clinical applicability resulted in the exclusion of many reports which highlights the need for further investigations employing outcomes established as important to parents and children.[22] While diarrhea
remains a concern with ondansetron administration the clinical impact appears to be negligible
with single dose regimens, however when multiple doses are administered this becomes more
of a concern.
This review has adhered to the latest methodological standards. Relevant evidence was
searched for extensively and this review included all studies regardless of language of publication. Although not all possible interventions were considered, this review focused on common
clinical intervention options and represents a comprehensive synthesis incorporating two key
perspectives: 1) patient-centered outcomes, and 2) developed countries.
This review has several limitations. It is limited by the challenges of synthesizing unrelated
outcomes which resulted in a limited body of evidence. Since this review focused on outpatient
studies, the results cannot be applied to the care of children managed at home by caregivers for
whom very limited data exists, or to the care of hospitalized children. The latter group, which
represents a fraction of children with AGE, has been the focus of most clinical trials. While the
ED setting may differ significantly from other outpatient settings and this might be a source of
heterogeneity, within each therapy the location was very consistent (e.g. ondansetron studied in
ED; probiotics studied in primary care). Since participant ages varied across the studies, planned
sub-analyses (i.e. < 5 years vs.  5 years) could not be conducted. Additionally, the only interventions evaluated are those currently being considered for routine use in developed countries;
interventions that are primarily considered for use only in developing nations (e.g. antibiotics,
zinc) were not evaluated. Although "exp Diarrhea/” was included in the original search strategy
(S2 File) data related to the duration and frequency of diarrhea was not abstracted originally as
these were not included in the a priori defined outcome measures. However, in the context of antiemetic evaluation, they were deemed to be important and thus were included in the current version of the SR. Lastly, despite attempts to minimize heterogeneity amongst different studies, it
could not be completely eliminated as studies included almost certainly varied in terms of infectious etiology, seasonality, and local factors influencing clinical decision making. Nonetheless,
the knowledge gaps identified can serve to guide future research efforts.
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Conclusions
Although some clinical practice guidelines endorse probiotic use, there is a paucity of supporting evidence for their use in developed countries. Routine probiotic use appears unjustified at
present and future studies employing patient-centered outcomes are needed. While further evidence supporting ORT is needed to expand its use, such studies may be challenging to justify
as expert opinion overwhelmingly supports its use as first-line therapy in children with AGE.
Ondansetron has a strong evidence base supporting use and the key will be ensuring that administration is directed at the populations included in the RCTs. It should be noted that
ondansetron use is not associated with reduction in ED revisits and it has the potential to increase diarrheal episodes. Moving forward, studies focusing on important outcomes and patient populations are needed to build a stronger evidence base to guide therapy for this
extremely common condition.
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